MRK · News · 20260912N

Keytruda Patent Expiration Outlook

Merck & Co., Inc. · 2026-09-12 · Importance 50 · Surprise 24

Third-party reporting identifies Keytruda’s expected 2028 patent expiration as a material strategic and revenue risk for Merck. Reports state that Merck will need to offset potential revenue loss through pipeline development and reduced reliance on Keytruda. No specific mitigation amount or timeline beyond the 2028 patent challenge is provided.

Key facts

• Analysts note Merck needs to offset potential revenue loss from Keytruda's 2028 patent expiration. source
• Analysts are focusing on Merck's strategies to reduce its reliance on Keytruda in anticipation of patent challenges in 2028. source